Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Pain, Postoperative 2Lung Neoplasms 2Inflammation 2Stomach Neoplasms 1Postoperative Nausea and Vomiting 1Pancreatic Neoplasms 1Neuroma, Acoustic 1Neoplasms 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Gynecological Laparoscopic Surgery 1Esophageal Neoplasms 1Emergence Delirium 1Chronic Pain 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Morphine 7Ketamine 5Fentanyl 4Sodium Chloride 3Saline Solution 3Lidocaine 3Educational Status 3Dexmedetomidine 3Cognitive Behavioral Therapy 3Anesthetics, Local 3Surveys and Questionnaires 2Pregabalin 2Mindfulness-Based Stress Reduction 2Hypnosis 2Bupivacaine 2Acetaminophen 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tianeptine 1siltuximab 1onabotulinum toxin A 1nabiximols 1morphine, naltrexone combination 1erenumab 1Yoga 1Waiting Lists 1Transcutaneous Electric Nerve Stimulation 1Tramadol 1Therapeutics 1Telemedicine 1Tea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chronic Pain × Sufentanil × Clear all
NCT00943566 2015-09-15

A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer

Labtec GmbH

Phase 2 Withdrawn

Neoplasms, Pain, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡